Volume 69 Received 13 December 2012 | ||||||||||
| ||||||||||
aDpto. Química Orgánica, Facultade de Química, Universidade de Vigo, E-36310 Vigo, Spain, and bUnidad de Difracción de Raios X de Monocristal, Servicio Determinación Estructural, Proteómica e Xenómica, CACTI-Universidade de Vigo, E-36310 Vigo, Spain
Correspondence e-mail: m.lois@uvigo.es
The chiral title compound, C19H32O2, contains a [4.3.0]-bicyclic moiety in which the shared C-C bond presents a trans configuration and a side chain in which the C=C double bond shows an E conformation. The conformations of five- and six-membered rings are envelope (with the bridgehead atom bearing the methyl substituent as the flap) and chair, respectively, with a dihedral angle of 4.08 (17)° between the idealized planes of the rings. In the crystal, the molecules are self-assembled via classical O-H
O hydrogen bonds, forming chains along [112]; these chains are linked by weak non-classical C-H
O hydrogen bonds, giving a two-dimensional supramolecular structure parallel to (010). The absolute configuration was established according to the configuration of the starting material.
The title compound is a precursor of the hormonally active form of vitamin D3. For general background to vitamin D3, see: Heaney (2008
); Henry (2011
). For related structures, see: Maehr & Uskokovic (2004
). For puckering parameters, see: Cremer & Pople (1975
).
|
|
| ||||||||||||||||||||||
Data collection: SMART (Bruker, 1998
); cell refinement: SAINT (Bruker, 1998
); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008
); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008
); molecular graphics: PLATON (Spek, 2009
) and Mercury (Macrae et al., 2006
); software used to prepare material for publication: SHELXTL (Sheldrick, 2008
).
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: PV2614 ).
This work was supported financially by the Spanish Ministry of Foreign Affairs and Cooperation (PCIA/030052/10) and the Xunta de Galicia (INCITE845B, INCITE08PXIB314255PR).
Bruker (1998). SMART and SAINT. Bruker AXS Inc., Madinson, Wisconsin, USA.
Cremer, D. & Pople, J. A. (1975). J. Am. Chem. Soc. 97, 1354-1358.
![[ISI]](../../../../../../logos/isiborder.gif)
Heaney, R. P. (2008). Clin. J. Am. Soc. Nephrol. 3, 1535-1541.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Henry, H. L. (2011). Best Pract. Res. Clin. Endocrinol. Metab. 25, 531-541.
![[PubMed]](../../../../../../logos/pubmedborder.gif)
Macrae, C. F., Edgington, P. R., McCabe, P., Pidcock, E., Shields, G. P., Taylor, R., Towler, M. & van de Streek, J. (2006). J. Appl. Cryst. 39, 453-457.
![[details]](../../../../../../j/graphics/details.gif)
Maehr, H. & Uskokovic, M. R. (2004). Eur. J. Org. Chem. pp. 1703-1713.
![[CrossRef]](../../../../../../logos/crossrefborder.gif)
Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
![[details]](../../../../../../a/graphics/details.gif)
Spek, A. L. (2009). Acta Cryst. D65, 148-155.
![[details]](../../../../../../d/graphics/details.gif)